CL2019001304A1 - Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica. - Google Patents

Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica.

Info

Publication number
CL2019001304A1
CL2019001304A1 CL2019001304A CL2019001304A CL2019001304A1 CL 2019001304 A1 CL2019001304 A1 CL 2019001304A1 CL 2019001304 A CL2019001304 A CL 2019001304A CL 2019001304 A CL2019001304 A CL 2019001304A CL 2019001304 A1 CL2019001304 A1 CL 2019001304A1
Authority
CL
Chile
Prior art keywords
pcsk9
atherosclerosis
ldl
cardiovascular disease
combination therapies
Prior art date
Application number
CL2019001304A
Other languages
English (en)
Spanish (es)
Inventor
Ransi Mudalinayake Somaratne
Robert Andrew Donald Scott
Scott Wasserman
Narimon Honarpour
Stephen Nicholls
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60484496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019001304(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2019001304A1 publication Critical patent/CL2019001304A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CL2019001304A 2016-11-14 2019-05-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica. CL2019001304A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662421685P 2016-11-14 2016-11-14
US201762471874P 2017-03-15 2017-03-15
US201762515117P 2017-06-05 2017-06-05
US201762581244P 2017-11-03 2017-11-03
US201762584600P 2017-11-10 2017-11-10

Publications (1)

Publication Number Publication Date
CL2019001304A1 true CL2019001304A1 (es) 2019-09-23

Family

ID=60484496

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019001304A CL2019001304A1 (es) 2016-11-14 2019-05-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica.
CL2020002993A CL2020002993A1 (es) 2016-11-14 2020-11-18 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020002993A CL2020002993A1 (es) 2016-11-14 2020-11-18 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica (divisional de solicitud no 1304-2019)

Country Status (17)

Country Link
US (1) US20200368350A1 (https=)
EP (1) EP3538149A2 (https=)
JP (3) JP2019533715A (https=)
KR (2) KR20190085963A (https=)
CN (1) CN110234350A (https=)
AU (2) AU2017356219A1 (https=)
BR (1) BR112019009726A2 (https=)
CA (1) CA3043700A1 (https=)
CL (2) CL2019001304A1 (https=)
CO (1) CO2019004814A2 (https=)
IL (2) IL326501A (https=)
JO (1) JOP20190112A1 (https=)
MA (1) MA46758A (https=)
MX (3) MX2019005627A (https=)
TN (1) TN2019000156A1 (https=)
WO (1) WO2018089912A2 (https=)
ZA (1) ZA201902975B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
US20210290580A1 (en) * 2018-07-31 2021-09-23 Wen Tan New use of carbamate ß phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
US12608440B2 (en) 2019-07-19 2026-04-21 Ebay Inc. Sample delta monitoring
CN112656792B (zh) * 2021-01-26 2022-07-05 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874149T3 (es) 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9493774B2 (en) * 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
NZ597504A (en) 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
KR20130118925A (ko) 2010-12-22 2013-10-30 제넨테크, 인크. 항-pcsk9 항체 및 사용 방법
AU2012214251A1 (en) 2011-02-11 2013-09-12 Novartis Ag PCSK9 antagonists
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
AU2015231713B2 (en) * 2014-03-17 2020-11-19 Regeneron Pharmaceuticals, Inc. Methods for reducing cardiovascular risk
CA2973116C (en) * 2015-01-09 2023-08-15 Global Genomics Group, LLC Blood based biomarkers for diagnosing atherosclerotic coronary artery disease

Also Published As

Publication number Publication date
BR112019009726A2 (pt) 2019-08-13
IL266579A (en) 2019-07-31
MX2025002106A (es) 2025-04-02
IL326501A (en) 2026-04-01
MX2024000805A (es) 2024-02-06
MA46758A (fr) 2019-09-18
AU2017356219A1 (en) 2019-05-30
EP3538149A2 (en) 2019-09-18
CN110234350A (zh) 2019-09-13
JP2025102770A (ja) 2025-07-08
ZA201902975B (en) 2020-01-29
CL2020002993A1 (es) 2021-05-14
WO2018089912A2 (en) 2018-05-17
JP2023071715A (ja) 2023-05-23
CO2019004814A2 (es) 2019-07-31
CA3043700A1 (en) 2018-05-17
AU2024278180A1 (en) 2025-01-09
KR20240096648A (ko) 2024-06-26
WO2018089912A3 (en) 2018-06-21
TN2019000156A1 (en) 2020-10-05
JP2019533715A (ja) 2019-11-21
JOP20190112A1 (ar) 2019-05-14
KR20190085963A (ko) 2019-07-19
US20200368350A1 (en) 2020-11-26
MX2019005627A (es) 2019-10-14

Similar Documents

Publication Publication Date Title
CL2019001304A1 (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerótica.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CR20170014A (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
CL2017002636A1 (es) Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
ECSP20082339A (es) Moduladores de la expresión de apol1
UY36026A (es) “variantes de hppd y métodos de uso”.
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2018007823A (es) Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal.
MX2017016774A (es) Agente terapeutico para la fibrosis.
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MX2019010931A (es) Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia.
PE20220250A1 (es) Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
SV2016005308A (es) Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
MX2016009567A (es) Composicion antifungica.